Nurses' clinical practice Portuguese: subcutaneous administration of trastuzumab (herceptin®) and rituximab (mabthera®)

Authors

Alice Monteiro Hospital de Dia, IPO Porto, Porto
Carlos Góis Hospital de Dia, IPO Coimbra, Coimbra
Cristina Lacerda Serviço de Oncologia, IPO Lisboa, Lisboa
Elisabete Valério Clínica da Mama, IPO Porto, Porto
Helena Xavier Hospital de Dia - Oncologia, Hospital Capuchos
Ortélia Dias Hospital de Dia - Oncologia, Hospital Santa Maria
Sandra Ponte Hospital de Dia, Hospital S. Francisco Xavier
Sara Torcato Parreira Hospital de Dia - Oncologia, Hospital Cuf

Keywords:

Rituximab, Trastuzumab, Subcutaneous, Nursing interventions, Good practices, Cancer nursing

Abstract

The subcutaneous formulations of Trastuzumab (Herceptin®) and Rituximab (MabThera®) are more comfortable for the people affected by cancer who need this type of treatment and are also easier to prescribe, prepare and administer. This type of formulations demands nurses to update their knowledge, so that good practices are assured in the health care setting. With the purpose to support nurses in this matter, the Portuguese Oncology Nursing Association developed two documents with recommendations for administration of subcutaneous Rituximab and Trastuzumab. A group of expert cancer nurses evaluated the applicability of those documents and concluded that they facilitate to standardize procedures and to guide nursing interventions, which might help in the education and follow-up of the people affected by cancer who are under this type of anti-cancer treatments.

Downloads

Download data is not yet available.

References

AEOP (2016a). Linhas de Consenso Linfoma Não-Hodgkin: utilização de Rituximab SC (MabThera 1400mg) em doentes com Linfoma Não-Hodgkin (LNH) – Recomendações para Enfermeiros. Associação de Enfermagem Oncológica Portuguesa;

AEOP (2016b). Linhas de Consenso Cancro da Mama: utilização de Trastuzumab SC em doentes com cancro de mama com expressão HER2+ - Recomendações para Enfermeiros. Associação de Enfermagem Oncológica Portuguesa;

Andrade, S. et al. (2014). Estudo de avaliação do Consumo de recursos hospitalares associados à administração de Trastuzumab; Revista Port Farmacoter, 6, 7-15;

Carlson, J.; Cox, K.; Bedwell, K.; Ku, M. (2015). Rituximab for subcutaneous delivery: Clinical management principles from a nursing perspective. International Journal of Nursing Practice, 21 (2), 1–13;

Martorell, P.; Heras, B.; Perez-Fidalgo, J.; Alvaro, M.; Martin, M.; Albanell, J.; Hernandez, A. (2014). Subcutaneus trastuzumab: drug development and current position. Clinical and Translational Oncology, 16, 859-864;

Pivot X, et al. (2013). PrefHer. The Lancet Oncology;

Rummel, M. (2015). PrefMab Study: Final Analysis Of Patient Satisfaction With Subcutaneous Versus Intravenous Rituximab In Previously Untreated Cd20+ Diffuse Large B-Cell Lymphoma Or Follicular Lymphoma. Value Health, 18 (7), A469;

Salar, A.; Bouabdallah, R.; McIntyre, C.; Sayyed, P.; Bittner, B. (2010). A Two-Stage Phase Ib Study to Investigate the Pharmacokinetics, Safety and Tolerability of Subcutaneous Rituximab In Patients with Follicular Lymphoma as Part of Maintenance Treatment. Blood, 116 (21), 2858;

Serverson Cherie, C. (2015). Evaluating the benefits of transitioning from intravenous to subcutaneous Rituximab for Alberta cancer patients. Canadian Oncology Nursing Journal, 25(3), 341-346.

Downloads

PDF (Português (Portugal))

Published

2018-06-20

How to Cite

Monteiro A, Góis C, Lacerda C, Valério E, Xavier H, Dias O, Ponte S, Torcato Parreira S. Nurses’ clinical practice Portuguese: subcutaneous administration of trastuzumab (herceptin®) and rituximab (mabthera®). Onco.News [Internet]. 2018 Jun. 20 [cited 2024 Nov. 29];(36):20-5. Available from: https://onco.news/index.php/journal/article/view/73